Treatment of Relapsed/Refractory Aplastic Anemia
Indian Journal of Hematology and Blood Transfusion · 2026-11 · 42 (6) · 2381-2399
DOI: 10.1007/s12288-026-02540-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 21.08.2026. Verfasst von Rahul Bhargava und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology and Bone Marrow Transplantation, Fortis Memorial Research Institute, Gurugram, Haryana India. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Relapsed or refractory aplastic anemia (AA) remains a challenging clinical scenario despite significant advances in first-line therapy. AA is an immune-mediated bone marrow failure characterized by pancytopenia and hypocellular marrow. In adult patients, first-line immunosuppressive therapy (IST) with horse antithymocyte globulin (ATG) plus cyclosporine A (CsA) achieves hematologic response rates of 60-80%, but 10-30% of severe AA cases will relapse after initial improvement, and a similar fraction may be refractory to initial therapy. Management of relapsed/refractory AA (R/R AA) requires a comprehensive, patient-tailored approach incorporating both pharmacologic therapies and hematopoietic stem cell transplantation (HSCT). Advances in the past decade have expanded treatment options. Second-line IST (e.g. repeat ATG or alemtuzumab) can rescue ~ 30-60% of patients, while the thrombopoietin receptor agonist eltrombopag has shown response rates around 40-60% in refractory AA. Newer TPO-agonists such as avatrombopag and romiplostim have demonstrated similar efficacy with favorable safety. Allogeneic HSCT remains the only curative therapy, and outcomes have improved markedly even for older patients and alternative donors. Salvage HSCT yields long-term failure-free survival superior to medical therapy in appropriate candidates, with 4-year overall survival ~ 80% in recent series. Notably, haploidentical donor HSCT with post-transplant cyclophosphamide has emerged as a viable option for patients lacking matched donors, achieving 1-year survival ~ 81% with minimal graft-vs-host disease (GVHD). Pediatric considerations include a lower threshold for upfront transplantation and unique supportive care needs. This review examines the current evidence (2017-2025) for treating R/R AA, including mechanisms of action of therapies, patient selection, outcomes, and adverse effects. We highlight real-world data, clinical trial results, and global perspectives (with a focus on resource-limited settings like India) to guide optimal management of relapsed or refractory AA in both adults and children.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology and Bone Marrow Transplantation, Fortis Memorial Research Institute, Gurugram, Haryana India.
ORCID-Profile: Rahul Bhargava
Zitieren
APA
Bhargava, R., Nathany, S., Makda, M., Swaminathan, A., & Dua, V. (2026). Treatment of Relapsed/Refractory Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion, 42(6), 2381-2399. https://doi.org/10.1007/s12288-026-02540-2
Vancouver
Bhargava R, Nathany S, Makda M, Swaminathan A, Dua V. Treatment of Relapsed/Refractory Aplastic Anemia. Indian Journal of Hematology and Blood Transfusion. 2026;42(6):2381-2399. doi:10.1007/s12288-026-02540-2
BibTeX
@article{Bhargava2026,
author = {Bhargava, Rahul and Nathany, Shrinidhi and Makda, Moin and Swaminathan, Anusha and Dua, Vikas},
title = {Treatment of Relapsed/Refractory Aplastic Anemia},
journal = {Indian Journal of Hematology and Blood Transfusion},
year = {2026},
volume = {42},
number = {6},
pages = {2381--2399},
doi = {10.1007/s12288-026-02540-2}
}
EUVIMED